Your browser is no longer supported. Please, upgrade your browser.
Settings
MNK Mallinckrodt plc daily Stock Chart
MNK [NYSE]
Mallinckrodt plc
Index- P/E- EPS (ttm)-43.55 Insider Own1.00% Shs Outstand87.66M Perf Week-15.97%
Market Cap1.60B Forward P/E2.26 EPS next Y8.04 Insider Trans0.23% Shs Float81.68M Perf Month-15.82%
Income-3630.40M PEG- EPS next Q1.71 Inst Own- Short Float30.79% Perf Quarter-9.81%
Sales3.22B P/S0.50 EPS this Y-421.90% Inst Trans-0.18% Short Ratio15.19 Perf Half Y-33.77%
Book/sh34.62 P/B0.53 EPS next Y-1.96% ROA-25.60% Target Price29.85 Perf Year39.25%
Cash/sh3.98 P/C4.57 EPS next 5Y9.17% ROE-64.30% 52W Range11.65 - 36.65 Perf YTD15.19%
Dividend- P/FCF2.96 EPS past 5Y9.79% ROI-36.70% 52W High-50.34% Beta2.25
Dividend %- Quick Ratio1.20 Sales past 5Y14.30% Gross Margin45.80% 52W Low56.22% ATR0.92
Employees3700 Current Ratio1.50 Sales Q/Q5.40% Oper. Margin- RSI (14)30.46 Volatility6.53% 4.36%
OptionableYes Debt/Eq2.11 EPS Q/Q-457.60% Profit Margin- Rel Volume0.75 Prev Close18.36
ShortableYes LT Debt/Eq2.10 EarningsMay 07 BMO Payout- Avg Volume1.66M Price18.20
Recom2.70 SMA20-15.85% SMA50-17.33% SMA200-26.19% Volume1,240,827 Change-0.87%
Mar-20-19Initiated SunTrust Hold
Nov-19-18Upgrade Canaccord Genuity Hold → Buy $34 → $40
Sep-11-18Downgrade Goldman Neutral → Sell
Aug-24-18Reiterated B. Riley FBR Neutral $20 → $37
Aug-08-18Reiterated Stifel Hold $18 → $30
Aug-08-18Downgrade Raymond James Outperform → Mkt Perform
May-09-18Reiterated Barclays Underweight $20 → $12
May-02-18Initiated B. Riley FBR, Inc. Neutral $15
Mar-09-18Reiterated Mizuho Neutral $21 → $16
Feb-02-18Downgrade Barclays Equal Weight → Underweight $23 → $20
Jan-09-18Reiterated Mizuho Neutral $22 → $21
Jan-03-18Initiated Leerink Partners Mkt Perform $26
Nov-08-17Reiterated Canaccord Genuity Buy $38 → $24
Nov-08-17Downgrade Wells Fargo Outperform → Market Perform
Nov-08-17Downgrade Goldman Buy → Neutral
Nov-08-17Downgrade Barclays Overweight → Equal Weight $65 → $23
Nov-07-17Downgrade Deutsche Bank Buy → Hold $44 → $28
Sep-28-17Initiated Goldman Buy $55
Sep-06-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Overweight $52
Apr-24-19 04:34PM  Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. PR Newswire
02:16PM  Mallinckrodt International Finance SA -- Moody's downgrades Mallinckrodt's CFR to B1; outlook negative Moody's
Apr-23-19 06:45AM  Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population PR Newswire
Apr-22-19 12:26PM  If You Had Bought Mallinckrodt (NYSE:MNK) Stock Five Years Ago, You'd Be Sitting On A 74% Loss, Today Simply Wall St.
Apr-18-19 06:45AM  Mallinckrodt Reports Top-Line Results from Proof-of-Concept Study of Nitric Oxide Gas in Ex-Vivo System of Human Lung Transplants PR Newswire
Apr-17-19 04:32PM  Why Sprint, Bank of New York Mellon, and Mallinckrodt Slumped Today Motley Fool -11.68%
Apr-16-19 05:50PM  Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know Zacks
10:10AM  Will Mallinckrodt (MNK) Beat Estimates Again in Its Next Earnings Report? Zacks
Apr-15-19 12:08PM  Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs Zacks
10:50AM  Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study Zacks
06:45AM  Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress (EASL) PR Newswire
Apr-12-19 10:48AM  Zacks Value Trader Highlights: G-III Apparel, General Motors, Legg Mason, Mallinckrodt and United Natural Foods Zacks
10:43AM  Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel Zacks
06:45AM  Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft® Regenerative Skin Tissue PR Newswire
Apr-11-19 01:41PM  Lessons from my Favorite Book for Value Investors Zacks
08:17AM  6 Valuable Price-to-Book Stocks to Buy as Slowdown Lurks Zacks
06:45AM  Mallinckrodt and Washington University St. Louis Select First Collaborative Research Endeavor PR Newswire
Apr-10-19 09:30AM  MNK vs. AMPH: Which Stock Is the Better Value Option? Zacks
Apr-09-19 05:50PM  Mallinckrodt (MNK) Dips More Than Broader Markets: What You Should Know Zacks
09:15AM  Comeback Gives S&P an 8-Session Winning Streak Zacks
06:45AM  Data Published on Acthar® Gel (repository corticotropin injection) Disease Status and Utilization Patterns in Uveitis Patients in Journal of Ocular Pharmacology and Therapeutics PR Newswire
Apr-08-19 09:30AM  Has Mallinckrodt public limited (MNK) Outpaced Other Medical Stocks This Year? Zacks
09:10AM  Is Mallinckrodt (MNK) Stock Undervalued Right Now? Zacks
Apr-03-19 05:50PM  Mallinckrodt (MNK) Stock Sinks As Market Gains: What You Should Know Zacks
Apr-02-19 03:29PM  St. Louis public companies on the rise in Q1, still trail national levels American City Business Journals
Apr-01-19 08:45PM  Suit: US drug agency deemed firm 'kingpin' in 'drug cartel' Associated Press
07:47PM  Suit: US drug agency deemed firm 'kingpin' in 'drug cartel' Associated Press
04:46PM  Supernus' ADHD Candidate Positive in 4th Phase III Study Zacks
Mar-28-19 05:45PM  Mallinckrodt Achieves Top Score in 2019 Corporate Equality Index for Third Year in a Row, Recognized as a Best Place to Work for LGBTQ Equality PR Newswire
09:30AM  Why Is Mallinckrodt (MNK) Down 12.1% Since Last Earnings Report? Zacks
Mar-27-19 05:50PM  Mallinckrodt (MNK) Gains As Market Dips: What You Should Know Zacks
09:05AM  Zacks.com featured expert Kevin Matras highlights: Mallinckrodt, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and General Motors Zacks
06:55AM  Mallinckrodt plc To Report Earnings Results For First Quarter 2019 PR Newswire
Mar-26-19 10:25AM  Mallinckrodt Announces 2019 Investigator Award for Pioneering Efforts in ECP Immunomodulation PR Newswire
09:15AM  Dow Manages Slight Gain Despite Anxious Market Zacks
08:50AM  Buy These 6 Low Price-to-Book Value Stocks for Solid Returns Zacks
Mar-25-19 09:30AM  MNK vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Mar-22-19 09:30AM  Is Mallinckrodt public limited (MNK) Stock Outpacing Its Medical Peers This Year? Zacks -7.18%
09:10AM  Is Mallinckrodt (MNK) Stock Undervalued Right Now? Zacks
Mar-21-19 05:45PM  Mallinckrodt (MNK) Gains But Lags Market: What You Should Know Zacks
Mar-19-19 11:51AM  Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients Zacks
11:49AM  Top Ranked Value Stocks to Buy for March 19th Zacks
Mar-18-19 06:45AM  Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO) PR Newswire
Mar-15-19 06:55AM  Mallinckrodt's Hobart, N.Y. and St. Louis, Mo. Sites Recognized as 2019 Manufacturing Leadership Award Winners PR Newswire
Mar-13-19 06:30AM  Look Out for Big Pharma Credit Downgrades This Year Barrons.com
Mar-12-19 09:55AM  Is Mallinckrodt (MNK) a Great Stock for Value Investors? Zacks
Mar-11-19 01:13PM  Opioid litigation concerns weigh on pharmaceutical loan borrowers Reuters
09:55AM  Add These 6 Low P/B Stocks to Your Portfolio in March Zacks
Mar-08-19 09:30AM  MNK vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Mar-06-19 09:15AM  Stocks Get Stuck Waiting for Trade Deal Zacks -5.05%
Mar-05-19 11:16AM  OxyContin Maker Purdue Pharma's Legal Entanglement, Explained Benzinga
Mar-04-19 06:55AM  Mallinckrodt Presents New Data on Real-World Resource Utilization Associated with Continuation of Systemic Treatment among Patients with Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting PR Newswire -6.66%
Mar-01-19 02:22PM  New Enterprise Associates is raising its biggest fund yet. Here's how much it's going for. American City Business Journals
06:55AM  Edited Transcript of MNK earnings conference call or presentation 26-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-27-19 03:30PM  Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 Zacks
08:32AM  Implied Volatility Surging for Mallinckrodt (MNK) Stock Options Zacks
Feb-26-19 04:11PM  This Pharma Stock Is Making A Bullish Run After Crushing Earnings Views Investor's Business Daily +10.20%
03:11PM  Mallinckrodt PLC (MNK) Q4 2018 Earnings Conference Call Transcript Motley Fool
02:30PM  Here's Why Mallinckrodt Jumped as Much as 26.8% Today Motley Fool
11:18AM  Mallinckrodt stock up 14% on earnings beat MarketWatch
07:58AM  Stocks making the biggest moves premarket: Home Depot, Caterpillar, Tesla & more CNBC
06:05AM  Mallinckrodt plc Reports Strong Fourth Quarter and Total Company 2018 Results, Announces 2019 Guidance and Strategic Priorities PR Newswire
Feb-25-19 01:41PM  Mallinckrodt's Q4 Earnings Preview Benzinga
09:00AM  Mallinckrodt Announces Extracorporeal Photopheresis (ECP) Research Collaboration Agreement With Transimmune AG PR Newswire
06:55AM  Mallinckrodt Announces Extracorporeal Photopheresis Research Collaboration Agreement With Transimmune AG PR Newswire
Feb-22-19 09:21AM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
09:06AM  Zacks.com featured highlights include: Mallinckrodt, Dell, American Axle, Daqo and General Motors Zacks
Feb-21-19 09:15AM  Another Round of Slight Gains Amid Choppy Session Zacks
07:21AM  6 Low Price-to-Book Stocks for Value Investors Zacks
03:00AM  Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease PR Newswire
Feb-20-19 03:09PM  Mylan (MYL) to Report Q4 Earnings: What's in the Offing? Zacks
06:55AM  Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease PR Newswire
Feb-19-19 05:47PM  Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects Zacks
Feb-18-19 08:16AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
Feb-15-19 04:08PM  What's in the Cards for Bausch Health (BHC) Q4 Earnings? Zacks
Feb-13-19 09:30AM  MNK vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Feb-12-19 06:55AM  Mallinckrodt To Present At Barclays Global Healthcare Conference PR Newswire
Feb-11-19 03:58PM  Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? Zacks
Feb-08-19 05:13PM  Teva (TEVA) to Report Q4 Earnings: What's in the Cards? Zacks
04:56PM  Tilray (TLRY) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-07-19 04:31PM  Exelixis (EXEL) to Report Q4 Earnings: What's in Store? Zacks
07:36AM  6 Low Price-to-Book Value Stocks to Buy in February Zacks
Feb-05-19 10:10AM  Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again Zacks
06:55AM  Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA) PR Newswire
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks
Feb-03-19 10:58PM  [$$] Want to Invest in a True Value Fund? Good Luck Finding One The Wall Street Journal
10:11PM  [$$] Want to Invest in a True 'Value' Fund? Good Luck Finding One The Wall Street Journal
Feb-01-19 05:58PM  Mylan's Generic Version of Advair Diskus Wins FDA Approval Zacks
Jan-28-19 09:30AM  MNK vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Jan-24-19 11:55AM  Goldman Sachs is worried about these stocks heading into their earnings reports CNBC
Jan-23-19 09:05AM  Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Dell Technologies, American Axle & Manufacturing, Magna International and General Motors Zacks
Jan-22-19 06:27AM  6 Promising Price-to-Book Value Stocks With Solid Prospects Zacks
Jan-16-19 05:06PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Jan-14-19 12:09PM  House Democrats launch drug-pricing probe into a dozen major health-care companies CNBC
12:03PM  The Mallinckrodt Spinoff Is a Short-Term Win GuruFocus.com
06:45AM  Mallinckrodt plc To Report Earnings Results For Fourth Quarter And Fiscal 2018 PR Newswire
Jan-11-19 09:30AM  MNK vs. AMPH: Which Stock Should Value Investors Buy Now? Zacks
Jan-10-19 02:54PM  Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility Zacks
Jan-03-19 05:43PM  Cara (CARA) Up on IDMC's Recommendation to Continue Trial Zacks
06:30AM  Data on Use of Mallinckrodt's H.P. Acthar® Gel (Repository Corticotropin Injection) in Patients with Rare Cause of Nephrotic Syndrome Published in Transplantation PR Newswire
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. It has collaboration with the Washington University School of Medicine in St. Louis. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trudeau MarkPresident and CEOMar 05Buy22.651,00022,650229,252Mar 06 08:18 AM
Trudeau MarkPresident and CEODec 10Buy20.181,00020,180236,254Dec 11 08:30 AM
Trudeau MarkPresident and CEOMay 16Buy15.543,00046,615269,961May 18 04:46 PM
Flynn James E10% OwnerMay 09Sale13.39312,9284,189,8188,308,455May 10 04:51 PM